REBECCA RWUBUSISI: Open Payments
NPI 1700423597 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,773 in 78 payments from 7 companies in 2025. Trend: 2023 $1,231 · 2024 $1,797 · 2025 $1,773
Food & beverage: $1,736Education: $37
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 28 | $746 |
| ViiV Healthcare Company | 19 | $418 |
| ABBVIE INC. | 18 | $275 |
| Merck Sharp & Dohme LLC | 8 | $236 |
| Astellas Pharma US Inc | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Invivyd Inc | 1 | $22 |
Products named: DOVATO, DALVANCE, ZERBAXA, APRETUDE, EMBLAVEO, Biktarvy, CABENUVA, Cresemba.
Industry payments across CO — which companies pay providers there.
